A decade or more after setting up the golden age of corporate venturing units were set up with a focus on life sciences and healthcare, such as US-listed conglomerate Alphabet’s GV (formerly known as Google Ventures) and US-listed drugs company Merck’s Global Health Innovation Fund (GHIF), and the returns have surpassed many expectations.

Workday Ventures has returned to back the telehealth platform developer’s series D round, which included Axa Venture Partners, Centene and GuideWell.

Intermountain Healthcare, Inova Health System, Ascension Ventures and St Luke’s Health System are all set to exit the medical payment software producer.

SoftBank Vision Fund led a $75m round valuing OKR platform developer WorkBoard at $800m while therapist network provider Headway hit a $750m valuation.

GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The health benefits software provider pushed its valuation to $1.5bn in a series F round led by Health Care Service Corporation and backed by Sun Life and SoftBank.

GV, Mass General Brigham Ventures and existing investor Lonza helped Affinia Therapeutics raise $110m that will fund the progress of its gene therapy candidates.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

NeoGenomics has agreed to buy portfolio company Inivata, a liquid biopsy platform developer, a year after it invested $25m.